[go: up one dir, main page]

WO2004045369A3 - Nuclear receptor-based diagnostic, therapeutic, and screening methods - Google Patents

Nuclear receptor-based diagnostic, therapeutic, and screening methods Download PDF

Info

Publication number
WO2004045369A3
WO2004045369A3 PCT/US2003/036229 US0336229W WO2004045369A3 WO 2004045369 A3 WO2004045369 A3 WO 2004045369A3 US 0336229 W US0336229 W US 0336229W WO 2004045369 A3 WO2004045369 A3 WO 2004045369A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuclear receptor
polynucleotides
methods
polypeptides
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036229
Other languages
French (fr)
Other versions
WO2004045369A2 (en
Inventor
George A Gaitanaris
John E Bergmann
Alexander Gracerov
John Hohmann
Fusheng Li
Linda Madisen
Kellie L Mcilwain
Maria N Pavlova
Demetri Vassilatis
Hongkui Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nura Inc
Original Assignee
Nura Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nura Inc filed Critical Nura Inc
Priority to AU2003295500A priority Critical patent/AU2003295500A1/en
Publication of WO2004045369A2 publication Critical patent/WO2004045369A2/en
Anticipated expiration legal-status Critical
Publication of WO2004045369A3 publication Critical patent/WO2004045369A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention features nuclear receptor polypeptides, polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the nuclear receptor polypeptides and polynucleotides of the invention, and for treating conditions associated with nuclear receptor dysfunction with the nuclear receptor polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate nuclear receptor activity or levels.
PCT/US2003/036229 2002-11-14 2003-11-12 Nuclear receptor-based diagnostic, therapeutic, and screening methods Ceased WO2004045369A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003295500A AU2003295500A1 (en) 2002-11-14 2003-11-12 Nuclear receptor-based diagnostic, therapeutic, and screening methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42630502P 2002-11-14 2002-11-14
US60/426,305 2002-11-14

Publications (2)

Publication Number Publication Date
WO2004045369A2 WO2004045369A2 (en) 2004-06-03
WO2004045369A3 true WO2004045369A3 (en) 2007-03-01

Family

ID=32326328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036229 Ceased WO2004045369A2 (en) 2002-11-14 2003-11-12 Nuclear receptor-based diagnostic, therapeutic, and screening methods

Country Status (2)

Country Link
AU (1) AU2003295500A1 (en)
WO (1) WO2004045369A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075983A2 (en) * 2004-02-07 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005075990A2 (en) * 2004-02-07 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
WO2006005460A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 2, group e, member 1 (nr2e1)
US9484123B2 (en) 2011-09-16 2016-11-01 Prc-Desoto International, Inc. Conductive sealant compositions
WO2014071281A1 (en) 2012-11-02 2014-05-08 The Johns Hopkins University Dna methylation biomarkers of post-partum depression risk
US9855314B2 (en) * 2013-03-01 2018-01-02 The Schepens Eye Research Insititute, Inc. Methods for modulating development and function of photoreceptor cells
RU2716479C1 (en) * 2018-09-13 2020-03-11 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" Method for prediction of response to cardiac resynchronising therapy in patients with chronic heart failure
RU2747679C1 (en) * 2020-07-09 2021-05-12 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Method for predicting clinical course of highly differentiated neuroendocrine pancreatic tumors
CN112725438B (en) * 2021-02-05 2023-08-22 深圳市宝安区妇幼保健院 Endometrial polyp methylation marker combination, detection kit and application
CN115851914A (en) * 2022-12-12 2023-03-28 复旦大学附属眼耳鼻喉科医院 Application of LOC107985869 in preparation of ophthalmoplegia specific auxiliary diagnostic reagent
CN116539902A (en) * 2023-07-05 2023-08-04 中国医学科学院北京协和医院 Application of differential lipid molecules as lipid markers and kit
CN116539901A (en) * 2023-07-06 2023-08-04 中国医学科学院北京协和医院 Application of differential metabolite as diagnostic marker and kit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ-GUASTI A. ET AL.: "Sex Differences in the Distribution of Androgen Receptors in the Human Hypothalamus", THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 425, 2000, pages 422 - 435, XP003008292 *
HAIDER N. ET AL.: "Mutation of a Nuclear Receptor Gene, NR2E3, Causes Enhanced S Cone Syndrome, a Disorder of Retinal Cell Fate", NATURE GENETICS, vol. 24, February 2000 (2000-02-01), pages 127 - 131, XP002203635 *

Also Published As

Publication number Publication date
WO2004045369A2 (en) 2004-06-03
AU2003295500A8 (en) 2004-06-15
AU2003295500A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
WO2004045369A3 (en) Nuclear receptor-based diagnostic, therapeutic, and screening methods
WO2008105797A3 (en) Polynucleotides encoding novel pcsk9 variants
WO2005026317A3 (en) Polynucleotides encoding novel variants of the trp channel family member, ltrpc3
WO2005001061A3 (en) Polynucleotides encoding novel adiponectin receptor variants
JPWO2002044362A1 (en) Diabetes treatment screening method
WO2008089281A3 (en) Methods of treating diabetes
WO2003063893A3 (en) Fgfr agonists
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
WO2000056405A3 (en) Human tumor necrosis factor receptor-like 2
WO2004083388A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2002072751A3 (en) Polynucleotides encoding a metalloprotease, mp-1
WO2004100886A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2002083856A3 (en) Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
WO2008061209A3 (en) G protein coupled receptors and uses thereof
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
WO2005052123A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor variant of the relaxin receptor, hgprbmy5v1, and variants thereof
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
WO2004094621A3 (en) Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
WO2003048316A3 (en) Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
WO2004090097A3 (en) Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
WO2002072755A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy27
WO2004015082A3 (en) Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
WO2005003299A3 (en) Polynucleotides encoding novel guanylate binding proteins (gbp's)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP